Smart Nanovesicle-Mediated Immunogenic Cell Death through Tumor Microenvironment Modulation for Effective Photodynamic Immunotherapy
Source abstract
Abstract
Combination therapy that could better balance immune activation and suppressive signals holds great potential in cancer immunotherapy. Herein, we serendipitously found that the pH-responsive nanovesicles (pRNVs) self-assembled from block copolymer polyethylene glycol-b-cationic polypeptide can not only serve as a nanocarrier but also cause immunogenic cell death (ICD) through preapoptotic exposure of calreticulin. After coencapsulation of a photosensitizer, 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) and an indoleamine 2,3-dioxygenase inhibitor, indoximod (IND), pRNVs/HPPH/IND at a single low dose elicited significant antitumor efficacy and abscopal effect following laser irradiation in a B16F10 melanoma tumor model. Treatment efficacy attributes to three key factors: (i) singlet oxygen generation by HPPH-mediated photodynamic therapy (PDT); (ii) increased dendritic cell (DC) recruitment and immune response provocation after ICD induced by pRNVs and PDT; and (iii) tumor microenvironment modulation by IND via enhancing P-S6K phosphorylation for CD8+ T cell development. This study exploited the nanocarrier to induce ICD for the host's immunity activation. The "all-in-one" smart nanovesicles allow the design of multifunctional materials to strengthen cancer immunotherapy efficacy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of PET Center, Xiangya Hospital, Central South University, Changsha 410008, China
Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland 20892, United States
Funding
National Institute of Biomedical Imaging and Bioengineering · National Natural Science Foundation of China
References (54)
Show source-provided references
1. 10.1038/nature1067310.1038/nature10673 ↗
2. 10.1038/nrclinonc.2013.20810.1038/nrclinonc.2013.208 ↗
3. 10.1038/nrclinonc.2014.11110.1038/nrclinonc.2014.111 ↗
4. 10.7150/thno.3338310.7150/thno.33383 ↗
5. 10.1038/nrc323910.1038/nrc3239 ↗
6. 10.1038/s41573-018-0006-z10.1038/s41573-018-0006-z ↗
7. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
8. 10.1021/acs.accounts.9b0014810.1021/acs.accounts.9b00148 ↗
9. 10.1016/j.nantod.2019.05.00410.1016/j.nantod.2019.05.004 ↗
10. 10.1021/acs.accounts.9b0007910.1021/acs.accounts.9b00079 ↗
11. 10.1002/adhm.20180132010.1002/adhm.201801320 ↗
12. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
13. 10.1038/nm152310.1038/nm1523 ↗
14. 10.1038/nrc338010.1038/nrc3380 ↗
15. 10.1038/s41551-018-0203-410.1038/s41551-018-0203-4 ↗
16. 10.1021/acsnano.8b0834610.1021/acsnano.8b08346 ↗
17. 10.1038/s41467-018-04605-x10.1038/s41467-018-04605-x ↗
18. 10.1038/nrc395810.1038/nrc3958 ↗
19. 10.1002/anie.20180488210.1002/anie.201804882 ↗
20. 10.1038/ncomms1249910.1038/ncomms12499 ↗
21. 10.1021/acs.chemrev.8b0062610.1021/acs.chemrev.8b00626 ↗
22. 10.1038/nrc189410.1038/nrc1894 ↗
23. 10.1002/anie.20180513810.1002/anie.201805138 ↗
24. 10.1002/anie.20190396810.1002/anie.201903968 ↗
25. 10.1021/cr900236h10.1021/cr900236h ↗
26. 10.1002/anie.20190327710.1002/anie.201903277 ↗
27. 10.7150/thno.2958010.7150/thno.29580 ↗
28. 10.1002/anie.20180524610.1002/anie.201805246 ↗
29. 10.1002/anie.20180198410.1002/anie.201801984 ↗
30. 10.1021/jacs.8b1350710.1021/jacs.8b13507 ↗
31. 10.7150/thno.2675810.7150/thno.26758 ↗
32. 10.1002/adfm.20190244010.1002/adfm.201902440 ↗
33. 10.1021/acsnano.8b0437110.1021/acsnano.8b04371 ↗
34. 10.1002/adma.20190092710.1002/adma.201900927 ↗
35. 10.1002/adfm.20180468810.1002/adfm.201804688 ↗
36. 10.1002/adma.20190049910.1002/adma.201900499 ↗
37. 10.1002/adma.20180332210.1002/adma.201803322 ↗
38. 10.7150/thno.2943110.7150/thno.29431 ↗
39. 10.1016/j.nantod.2018.06.00810.1016/j.nantod.2018.06.008 ↗
40. 10.7150/thno.2482110.7150/thno.24821 ↗
41. 10.1021/acsnano.8b0589310.1021/acsnano.8b05893 ↗
42. 10.1038/s41467-017-01651-910.1038/s41467-017-01651-9 ↗
43. 10.1002/adma.20170711210.1002/adma.201707112 ↗
44. 10.1021/acs.nanolett.8b0107110.1021/acs.nanolett.8b01071 ↗
45. 10.1002/anie.20190628810.1002/anie.201906288 ↗
46. 10.1111/j.1600-065X.2008.00610.x10.1111/j.1600-065X.2008.00610.x ↗
47. 10.1016/j.it.2012.10.00110.1016/j.it.2012.10.001 ↗
48. 10.1016/j.it.2016.01.00210.1016/j.it.2016.01.002 ↗
49. 10.1002/anie.20180042210.1002/anie.201800422 ↗
50. 10.1002/advs.20170089110.1002/advs.201700891 ↗
51. 10.1021/acsnano.8b0518910.1021/acsnano.8b05189 ↗
52. 10.1038/s41467-017-01386-710.1038/s41467-017-01386-7 ↗
53. 10.1002/adma.20170573710.1002/adma.201705737 ↗
54. 10.1021/bm801127d10.1021/bm801127d ↗